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General Methods
All commercial solvents and reagents were used as obtained without further purification, except for CH 2 Cl 2 which was distilled before use. Water was purified by a Milli-Q system and degassed by letting through nitrogen gas. All reactions were carried out under a nitrogen atmosphere. Semi-automatic flash chromatography was performed using Merck silica gel 60 (0.040-0.063 mm), on a Biotage HPFC SP4 Flash Purification System. 1 H and 13 C NMR spectra were recorded at 300 K on a Bruker Avance III 400 operating at 400 MHz and 101 MHz, respectively, with chemical shifts calibrated relative to solvent residual peaks ( 1 H NMR (DMSO-d 6 ): δ 2.50 ppm;
1 H NMR (CDCl 3 ): δ 7.26 ppm; 13 C NMR (DMSO-d 6 ): δ 39.52 ppm; 13 C NMR (CDCl 3 ): δ 77.16 ppm). Assignments are based on chemical shifts and/or COSY, HSQC and NOESY spectra. Mass spectra were recorded on a Bruker MicroTOF-Q II (ESI) spectrometer. Reactions were monitored by thin-layer chromatography (TLC) carried out on 0.25 mm E. Merck silica gel plates (60F-254) using UV-light and HPLC using a Dionex 120A C18 column (5µ, 4.6x150 mm) with gradient elution of MeCN and water, both solvents containing 0.05% trifluoroacetic acid (TFA), at a flow rate of 1 mL min -1 and UV detection at 230, 254 and 320 nm. HPLC purification was performed by using a Phenomenex Luna C18 5μ column (250x21.20 mm) with gradient elution of MeCN and water, both solvents containing 0.05% TFA, at a flow rate of 20 mL min -1 .
Synthesis of phenanthroline ligands
Ligands L1(DPPhen) 1 and G 2 were prepared as described previously.
N
,N 7 -Dimethyl-1,10-phenanthroline-4,7-diamine (Ligand L2)
A sealed vial containing 4,7-dichloro-1,10-phenanthroline (300 mg, 1.2 mmol) and methylamine (5.0 mL, 33% in EtOH, 40 mmol) was heated in a microwave reactor (Emrys Creator) at 150 °C for 40 min to give an orange mixture with a precipitate. The precipitate was isolated by filtration, washed with water, ethanol and diethyl ether, and dried under vacuum to give the title compound as a pale yellow solid (255 mg, 89% yield 
Reaction optimisation
Entry 1: A reaction tube equipped with a magnetic stirring bar was charged with CuBr (3.6 mg, 0.025 mmol), ligand (L1, 15.9 mg, 0.05 mmol), adenine (1, 81 mg, 0.60 mmol) and KOH (56.1 mg, 1.0 mmol). The tube was sealed with a rubber septum, evacuated and back-filled with nitrogen three times. EtOH/H 2 O (4:1 v/v, 1 mL) and iodobenzene (56 µL, 0.50 mmol) was added by syringe. The rubber septum was exchanged with a cap designed to withstand moderate pressure under a stream of nitrogen and the reaction tube was placed in a preheated oil bath at 120 °C. After 21 hours, the reaction mixture was cooled to RT, silica (1.5 g) was added and the mixture was concentrated to dryness on a rotary evaporator. The dry residue was purified by semi-automated flash column chromatography (Biotage SNAP 10 g, MeOH in CH 2 Cl 2 (3%  5%)), to provide 49 mg (46%) of 9-phenyladenine (2).
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Entries 2-19 were performed by the same procedure, but with the modifications indicated in Table 1 .
General procedure for N 9 -arylation of adenine ( 
3-(6-Aminopurin-9-yl)phenol (3a)
Following the general procedure using 3-iodophenol (165 mg, 0.75 mmol) provided the title compound as a white solid after semi-automated flash chromatography (Biotage SNAP 10 g, MeOH in CH 2 Cl 2 (4%  7%)), followed by a recrystallisation from water. Yield: 101 mg (89% 
9-(4-Aminophenyl)purin-6-amine (3b)
Using 4-iodoaniline: Following the general procedure using 4-iodoaniline (164 mg, 0.75 mmol) and heating for 21 hours provided the title compound as a pale tan solid after semi-automated flash chromatography (Biotage SNAP 10 g, MeOH in CH 2 Cl 2 (6%  10%)), followed by a recrystallisation from water. Yield: 100 mg (88%).
Using 4-bromoaniline:
Following the general procedure using 4-bromoaniline (129 mg, 0.75 mmol) and heating for 48 hours provided the title compound as a pale tan solid after semi-automated flash chromatography (Biotage SNAP 25 g, 10% MeOH in CH 2 Cl 2 ). Yield: 86 mg (76%). 
9-(4-Aminophenyl
3-(6-Aminopurin-9-yl)benzoic acid (3c)
N N N N NH 2
COOH
Following the general procedure using 3-iodobenzoic acid (186 mg, 0.75 mmol) provided the title compound as a tan solid after semi-automated flash chromatography (Biotage SNAP 25 g, MeOH/AcOH 2:1 in CH 2 Cl 2 (6%  12%)), followed by a recrystallisation from MeOH. Yield: 84 mg (66% 
9-(3-(Trifluoromethyl)phenyl)purin-6-amine (3e)
Following the general procedure using 1-iodo-3-(trifluoromethyl)benzene (204 
9-(3-Nitrophenyl)purin-6-amine (3f)
Following the general procedure using 1-iodo-3-nitrobenzene (187 mg, 0.75 mmol) provided the title compound as a yellow solid after semi-automated flash chromatography (Biotage SNAP 10 g, MeOH in CH 2 Cl 2 (3%  5%)), followed by a recrystallisation from water. Yield: 104 mg (81% 
9-(Thiophen-3-yl)purin-6-amine (3k)
Following the general procedure using 3-bromothiophene (122 mg, 0.75 mmol) provided the title compound as a white solid after semi-automated flash chromatography (Biotage SNAP 10 g, MeOH in CH 2 Cl 2 (4%  8%) 
4-(6-Aminopurin-9-yl)phenol (3l)
9-(4-Fluorophenyl)purin-6-amine (3n)
Following the general procedure using 1-bromo-4-fluorobenzene (131 mg, 0.75 mmol) provided the title compound as a white solid after semi-automated flash chromatography (Biotage SNAP 10 g, MeOH in CH 2 Cl 2 (3%  5%) 
9-(4-(2-Aminoethyl)phenyl)purin-6-amine (3p)
Following the general procedure using 4-bromophenethyl amine (151 
N-(4-(6-Aminopurin-9-yl)phenethyl)formamide
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Synthetic procedure for N-arylation of various purines (Table 3 )
Preparation of 8-methyltheophylline (4d)
A sealed vial containing 5,6-diamino-1,3-dimethyluracil hydrate (565 mg, 3.0 mmol), acetic anhydride (0.31 mL, 3.3 mmol) and pyridine (6 mL) was heated in a microwave reactor (Emrys Creator) at 110 °C for 20 min to give a red mixture with a precipitate. The solvent was evaporated under vacuum to dryness. The resulting amide was converted to benzimidazole by treatment with t-BuOK (1.01 g, 9.0 mmol) in isopropyl alcohol (14 mL) at 60 °C. After 16 hours, the reaction mixture was cooled to RT, silica (5 g) was added and the mixture was concentrated to dryness on a rotary evaporator. The dry residue was purified by semi-automated flash column chromatography (Biotage SNAP 25 g, MeOH in CH 2 Cl 2 (3%  4.5%)), to provide 382 mg (66%) of 8-methyltheophylline (4d 
General procedure A -purine, 2,6-diaminopurine, theophylline and 8-methyltheophylline (4a-d):
A reaction tube equipped with a magnetic stirring bar was charged with CuBr (3.6 mg, 0.025 mmol), ligand (L3, 14.9 mg, 0.05 mmol), sodium ascorbate (10 mg, 0.05 mmol), the purine substrate (4a, 4b, 4c or 4d, 0.50 mmol) and KOH (56.1 mg, 1.0 mmol). The tube was sealed with a rubber septum, evacuated and back-filled with nitrogen three times. Then DMF/H 2 O (4:1 v/v, 1 mL) and aryl halide (0.75 mmol) was added by syringe. The rubber septum was exchanged with a cap designed to withstand moderate pressure under a stream of nitrogen and the reaction tube was placed in a preheated oil bath at 120 °C. After 21 hours or 48 hours, the reaction mixture was cooled to RT, silica (1.5 g) was added and the mixture was concentrated to dryness on a rotary evaporator. The dry residue was purified by semi-automated flash column chromatography.
General procedure B -guanine and hypoxanthine (4e and 4f): A reaction tube equipped with a magnetic stirring bar was charged with CuBr (3.6 mg, 0.025 mmol), ligand (L3, 14.9 mg, 0.05 mmol), the purine substrate (4e or 4f, 0.50 mmol) and KOH (56.1 mg, 1.0 mmol). The tube was sealed with a rubber septum, evacuated and back-filled with nitrogen three times. Then DMSO/H 2 O (4:1 v/v, 1 mL) and aryl halide (0.75 mmol) was added by syringe. The rubber septum was exchanged with a cap designed to withstand moderate pressure under a stream of nitrogen and the reaction tube was placed in a preheated oil bath at 120 °C. After 6-48 hours, the reaction mixture was cooled to RT, silica (1.5 g) was added and the mixture concentrated to dryness on a rotary evaporator at 60 °C. The dry residue was purified by semi-automated flash column chromatography.
9-Phenylpurine (5a) and 7-phenylpurine(6a)
Using iodobenzene: Synthesised by general procedure A using iodobenzene (153 mg, 0.75 mmol) and heating for 21 hours. Purification by semi-automated flash chromatography (Biotage SNAP 10 g, MeOH in CH 2 Cl 2 (2%  3%)) gave 61 mg (62%) of 9-phenylpurine (5a) and 7 mg (7%) of 7-phenylpurine (6a), both products as pale brown solids.
Using bromobenzene: Synthesised by general procedure A using bromobenzene (118 mg, 0.75 mmol) and heating for 48 hours. Purification by semi-automated flash chromatography (Biotage SNAP 10 g, MeOH in CH 2 Cl 2 (2%  3%)) gave 63 mg (64%) of 9-phenylpurine (5a) and 3 mg (3%) of 7-phenylpurine (6a), both products as pale brown solids. 9-Phenylhypoxanthine (5f) and 7-phenylhypoxanthine (6f)
Using iodobenzene: Synthesised by general procedure B using iodobenzene (153 mg, 0.75 mmol) and heating for 3 hours, after which the starting material was almost consumed, and diarylated products had started to form. Purification by semi-automated flash chromatography (Biotage SNAP 10 g, MeOH in CH 2 Cl 2 (3%  5%)) gave a mixture of two isomers: 9-phenylhypoxanthine (5f) and 7-phenylhypoxanthine (6f) that were separated on HPLC (10-21% MeCN in H 2 O (0-6 min), R t (6f) = 4.4 min, R t (5f) = 5.3 min) to give 46 mg (43%) of 5f and 15 mg (14%) of 6f, both as white solids.
Using bromobenzene: Synthesised by general procedure B using bromobenzene (118 mg, 0.75 mmol) and heating for 32 hours, after which the starting material was almost consumed, and diarylated products had started to form. Purification by semi-automated flash chromatography (Biotage SNAP 10 g, MeOH in CH 2 Cl 2 (3%  5%)) gave a mixture of two isomers: 9-phenylhypoxanthine (5f) and 7-phenylhypoxanthine (6f) that were separated on HPLC (10-21% MeCN in H 2 O (0-6 min), R t (6f) = 4.4 min, R t (5f) = 5.3 min) to give 51 mg (48%) of 5f and 12 mg (11%) of 6f, both as white solids. 
9-phenylhypoxanthine
